Sulindac

SKU: orb1310592

Description

Sulindac is a prodrug NSAID metabolized in vivo to an active form that induces apoptosis by inhibiting cGMP phosphodiesterase. It is used in cancer research, particularly in studies of colorectal and prostate cancer, for investigating apoptotic pathways in both cellular and animal models.

Research Area

Cell Biology, Immunology & Inflammation, Neuroscience, Pharmacology & Drug Discovery, Signal Transduction

Key Properties

• CAS Number: 38194-50-2
• MW: 356.41
• Purity: 99.09% (May vary between batches)
• Formula: C₂₀H₁₇FO₃S
• SMILES: C(=C/1\C=2C(C(CC(O)=O)=C1C)=CC(F)=CC2)\C3=CC=C(S(C)=O)C=C3
• Target: COX,NF-κB,Autophagy,PD-1/PD-L1
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (5.61 mM);Ethanol:9 mg/mL (25.25 mM);DMSO:250 mg/mL (701.44 mM)

Bioactivity

• In Vivo:
  In colorectal cancer (CRC) cell lines, Sulindac and its metabolites sulindac sulfide and sulindac sulfone inhibit the NF-κB pathway, reducing IKKbeta kinase activity mediated by Sulindac. In HT-29 cells, Sulindac significantly reduces cell growth. Sulindac inhibits cell proliferation across various epithelial and fibroblast tumor cell lines. In CRC cell lines DLD1 and SW480, Sulindac suppresses beta-catenin/TCF-mediated gene transcription and decreases levels of non-phosphorylated beta-catenin.
• In Vitro:
  In intestinal tissues of Min/+ mice, Sulindac does not alter the levels of PGE2 and LTB4 but reduces the number of tumors. Within a mouse model of familial adenomatous polyposis, Sulindac decreases small intestine COX-2 and prostaglandin E (2), thereby inhibiting tumor formation.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

epithelial-mesenchymal transition (EMT), FDA, MK 231, MK231, MK-231, migration, immunomodulatory agent, Autophagy, Arthrocine, Clinoril, colorectal cancer (CRC), COX, Sulindac, Sulindac sulfoxide, pMMR, SIRT1

Compound Identifiers

PubChem CID

1548887